Detailed results from one of AstraZeneca’s (AZN.L), opens new tab key lung cancer trials released on Monday showed that its experimental precision drug did not significantly improve overall survival results for patients in the trial.
The overall survival, or OS rates, in the TROPION-Lung01 trial “did not reach statistical significance”, the company said in a presentation at the World Conference on Lung Cancer in San Diego.
The late-stage trial has been closely watched by investors and by analysts who forecast that the drug, known as Dato-DXd, could potentially be another best-selling medicine for the company.
The trial compared the two treatments — AstraZeneca’s drug and chemotherapy — of patients whose non-small cell lung cancer had returned after one or two prior treatment attempts.
